1. Home
  2. NMZ vs FTRE Comparison

NMZ vs FTRE Comparison

Compare NMZ & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Municipal High Income Opportunity Fund $0.01 par value per share

NMZ

Nuveen Municipal High Income Opportunity Fund $0.01 par value per share

HOLD

Current Price

$10.48

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo Fortrea Holdings Inc.

FTRE

Fortrea Holdings Inc.

HOLD

Current Price

$17.39

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMZ
FTRE
Founded
2003
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
NMZ
FTRE
Price
$10.48
$17.39
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$14.06
AVG Volume (30 Days)
720.9K
1.4M
Earning Date
01-01-0001
05-05-2026
Dividend Yield
5.08%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,723,400,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.09
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.00
52 Week Low
$9.83
$4.46
52 Week High
$10.77
$18.67

Technical Indicators

Market Signals
Indicator
NMZ
FTRE
Relative Strength Index (RSI) 61.52 62.63
Support Level $10.25 $15.40
Resistance Level $10.51 $18.08
Average True Range (ATR) 0.10 0.98
MACD 0.02 -0.00
Stochastic Oscillator 98.65 73.63

Price Performance

Historical Comparison
NMZ
FTRE

About NMZ Nuveen Municipal High Income Opportunity Fund $0.01 par value per share

Nuveen Municipal High Income Opp Fund is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide high current income exempt from regular federal income tax. The Fund's secondary investment objective is to seek an attractive total return consistent with its primary objective.

About FTRE Fortrea Holdings Inc.

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.

Share on Social Networks: